$VYGR
Voyager Therapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000155837021006582 Filed on May 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $6.501M $18.07M
YoY Change -64.02% 247.64%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.700M $10.20M
YoY Change -4.9% 5.15%
% of Gross Profit
Research & Development $22.35M $32.29M
YoY Change -30.8% 30.06%
% of Gross Profit
Depreciation & Amortization $1.274M $842.0K
YoY Change 51.31% 36.69%
% of Gross Profit
Operating Expenses $32.09M $42.50M
YoY Change -24.49% 23.22%
Operating Profit -$25.59M -$24.43M
YoY Change 4.73% -16.59%
Interest Expense $19.00K $978.0K
YoY Change -98.06% -14.59%
% of Operating Profit
Other Income/Expense, Net $3.940M $170.0K
YoY Change 2217.65% -91.99%
Pretax Income -$21.60M -$24.30M
YoY Change -11.11% -10.66%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$21.65M -$24.26M
YoY Change -10.77% -10.7%
Net Earnings / Revenue -333.01% -134.29%
Basic Earnings Per Share -$0.58
Diluted Earnings Per Share -$0.58 -$656.8K
COMMON SHARES
Basic Shares Outstanding 37.50M 37.15M
Diluted Shares Outstanding 37.50M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $161.5M $250.9M
YoY Change -35.63% -30.01%
Cash & Equivalents $117.8M $165.2M
Short-Term Investments $43.70M $85.70M
Other Short-Term Assets $10.10M $5.300M
YoY Change 90.57% -20.9%
Inventory
Prepaid Expenses
Receivables $4.300M $16.30M
Other Receivables $0.00 $0.00
Total Short-Term Assets $175.8M $272.5M
YoY Change -35.47% -25.39%
LONG-TERM ASSETS
Property, Plant & Equipment $24.52M $18.59M
YoY Change 31.93% -57.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.400M
YoY Change 7.69%
Other Assets $2.200M $2.400M
YoY Change -8.33% 60.0%
Total Long-Term Assets $61.88M $50.13M
YoY Change 23.43% 8.75%
TOTAL ASSETS
Total Short-Term Assets $175.8M $272.5M
Total Long-Term Assets $61.88M $50.13M
Total Assets $237.7M $322.6M
YoY Change -26.31% -21.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.177M $4.815M
YoY Change -34.02% 109.35%
Accrued Expenses $10.54M $17.49M
YoY Change -39.78% 88.1%
Deferred Revenue $6.443M $46.92M
YoY Change -86.27%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.75M $72.54M
YoY Change -65.88% 23.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $43.14M $31.09M
YoY Change 38.78% -2.77%
Total Long-Term Liabilities $43.14M $31.09M
YoY Change 38.78% -2.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.75M $72.54M
Total Long-Term Liabilities $43.14M $31.09M
Total Liabilities $101.5M $242.9M
YoY Change -58.2% -21.84%
SHAREHOLDERS EQUITY
Retained Earnings -$297.6M -$336.9M
YoY Change -11.67%
Common Stock $38.00K $37.00K
YoY Change 2.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $136.2M $79.76M
YoY Change
Total Liabilities & Shareholders Equity $237.7M $322.6M
YoY Change -26.31% -21.56%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$21.65M -$24.26M
YoY Change -10.77% -10.7%
Depreciation, Depletion And Amortization $1.274M $842.0K
YoY Change 51.31% 36.69%
Cash From Operating Activities -$21.29M -$28.80M
YoY Change -26.06% -123.01%
INVESTING ACTIVITIES
Capital Expenditures $375.0K $1.507M
YoY Change -75.12% 36.5%
Acquisitions
YoY Change
Other Investing Activities $35.00M $110.5M
YoY Change -68.33% -181.49%
Cash From Investing Activities $34.63M $109.0M
YoY Change -68.23% -179.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 28.00K 34.00K
YoY Change -17.65% -99.96%
NET CHANGE
Cash From Operating Activities -21.29M -28.80M
Cash From Investing Activities 34.63M 109.0M
Cash From Financing Activities 28.00K 34.00K
Net Change In Cash 13.36M 80.23M
YoY Change -83.35% 20.82%
FREE CASH FLOW
Cash From Operating Activities -$21.29M -$28.80M
Capital Expenditures $375.0K $1.507M
Free Cash Flow -$21.67M -$30.31M
YoY Change -28.5% -124.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Trading Symbol
TradingSymbol
VYGR
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37728183
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117799000
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3003182
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
75 Sidney Street
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2021Q1 dei City Area Code
CityAreaCode
857
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
259-5340
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2020Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37368027
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37556055
CY2021Q1 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2020Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherCurrentLiabilitiesMember
CY2021Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherNoncurrentLiabilitiesMember
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001640266
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-37625
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Voyager Therapeutics, Inc.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
43707000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104440000
CY2021Q1 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
2247000
CY2020Q4 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
2316000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
76698000
CY2021Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
4253000
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8012000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10078000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8619000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
175837000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
197769000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24520000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25435000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
35113000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
36064000
CY2021Q1 us-gaap Assets
Assets
237717000
CY2020Q4 us-gaap Assets
Assets
261584000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3177000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
634000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10535000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14205000
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4596000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4198000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6443000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7729000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
24751000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26766000
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
33614000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
36088000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43144000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44410000
CY2021Q1 us-gaap Liabilities
Liabilities
101509000
CY2020Q4 us-gaap Liabilities
Liabilities
107264000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37556055
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37368027
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
38000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
433849000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
430324000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-123000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-134000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21638000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-297556000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275907000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
136208000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
154320000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
237717000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
261584000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6501000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18067000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22346000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32294000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9744000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10206000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
32090000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
42500000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-25589000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24433000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
19000
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
978000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3921000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-808000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3940000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
170000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-21649000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-24263000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
525000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
11000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
525000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23738000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37501065
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36963255
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
99512000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
34000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3949000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
525000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-24263000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
79757000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
154320000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3498000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-21649000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
136208000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-21649000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-24263000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28000
CY2020Q1 vygr Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-774000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3601000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4040000
CY2021Q1 us-gaap Depreciation
Depreciation
1274000
CY2020Q1 us-gaap Depreciation
Depreciation
842000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-102000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
188000
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3882000
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-808000
CY2021Q1 vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-3759000
CY2020Q1 vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-2213000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-323000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
55000
CY2021Q1 vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-951000
CY2020Q1 vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-734000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-69000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-69000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2543000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
745000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3757000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4626000
CY2021Q1 vygr Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-868000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3760000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8343000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21294000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28798000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
375000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1507000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
35000000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
110500000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
34625000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
108993000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
34000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13359000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
80229000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106219000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86777000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119578000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167006000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
17000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
65000
CY2021Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VOYAGER THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">NOTE</b><b style="font-weight:bold;">S TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times';">Voyager Therapeutics, Inc. (the “Company”) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from serious neurological diseases. The Company is focused on neurological diseases where it believes an adeno-associated virus (“AAV”) gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The Company has built a gene therapy platform that it believes positions itself to be a leading company at the intersection of AAV gene therapy and severe neurological disease. The Company’s gene therapy platform enables it to engineer, optimize, manufacture and deliver its AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times';">Additionally, the Company is working to identify novel AAV capsids, which are the outer viral protein shells that enclose the genetic material of the virus payload. The Company’s team of experts in the fields of AAV gene therapy and neuroscience first identifies and selects severe neurological diseases that are well-suited for treatment using AAV gene therapy. The Company then engineers and optimizes AAV vectors for delivery of the virus payload to the targeted tissue or cells. The Company’s manufacturing process employs an established system that it believes will enable production of high quality AAV vectors at commercial-scale. I</span>n addition to the Company’s capsid optimization efforts, it leverages novel delivery paradigms, established routes of administration, and advances in dosing techniques to optimize delivery of its AAV gene therapies to target tissues, regions and cell types that are critical to the disease of interest. The Company believes it can achieve this directly, with targeted infusions to discrete regions of the brain, the spinal cord, or systemically, in conjunction with its novel capsids.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times';">The Company’s business strategy focuses on discovering, developing, manufacturing and commercializing its gene therapy programs. As part of this strategy, the Company has developed core competencies specific to AAV gene therapy development and manufacturing and is beginning to build its commercial infrastructure. This business strategy also includes business development activities that may include in-licensing activities or partnering certain programs in certain geographies with collaborators, as the Company has demonstrated through its ongoing collaboration with Neurocrine Biosciences, Inc. (the “Neurocrine Collaboration Agreement”). The Company is devoting substantially all of its efforts to product research and development, market development, and raising capital. The Company is subject to risks common to companies in the biotechnology and gene therapy industries, including but not limited to, the need to obtain sufficient capital to continue to fund its operations, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for its product candidates, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary information and technology, protection against data breaches and other cybersecurity threats, compliance with government regulations, development by competitors of technological innovations, and ability to transition from pilot-scale manufacturing to large-scale production of products. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring annual net operating losses. As of March 31, 2021, the Company had an accumulated deficit of $297.6 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities and funding from its prior collaborations with <span style="font-family:'Times';">Sanofi Genzyme Corporation (“Sanofi Genzyme”), AbbVie Biotechnology Ltd and AbbVie Ireland Unlimited Company (collectively, “AbbVie”), and its ongoing collaboration with Neurocrine Biosciences, Inc. (“Neurocrine”)</span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Through March 31, 2021, the Company has raised approximately $640.0 million of proceeds from sales of convertible preferred stock and common stock, including its initial public offering and follow-on public offering, and from its collaboration agreements. <span style="background-color:#ffffff;">As of March 31, 2021, the Company had cash, cash equivalents, and marketable debt securities</span> of $153.1 million. <span style="background-color:#ffffff;">Based upon its current operating plan, the Company expects that its existing cash, cash equivalents, and marketable debt securities, as well as ongoing reimbursement amounts expected from development </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">costs related to the Neurocrine Collaboration Agreement, will enable the Company to meet its planned operating expenses and capital expenditure requirements into mid-2022</span><span style="background-color:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenue from collaboration partners on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.</p>
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-297600000
CY2021Q1 vygr Proceeds From Issuance Of Equity And Collaboration Agreements
ProceedsFromIssuanceOfEquityAndCollaborationAgreements
640000000.0
CY2021Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
153100000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Certain reclassifications have been made to prior periods to conform to current period presentation.</p>
CY2020Q4 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
175560000
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
36466000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7241000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
43707000
CY2021Q1 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
145621000
CY2021Q1 vygr Money Market Funds And Marketable Securities Gross Unrealized Gain Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedGainBeforeTax
7241000
CY2021Q1 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
152862000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
71568000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5136000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
76698000
CY2020Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Gain Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedGainBeforeTax
5136000
CY2020Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
6000
CY2020Q4 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
180690000
CY2021Q1 vygr Debt Securities Contractual Maturity Period
DebtSecuritiesContractualMaturityPeriod
P1Y
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117799000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
165227000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
1779000
CY2020Q1 us-gaap Restricted Cash
RestrictedCash
1779000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119578000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167006000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10535000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14205000
CY2021Q1 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6134000
CY2020Q4 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6624000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2963000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5857000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1279000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1228000
CY2021Q1 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
159000
CY2020Q4 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
496000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
6016000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8469000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8723000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8985000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
9644000
CY2021Q1 vygr Lessee Operating Lease Liability Payments Due Year Five And After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
19945000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
61783000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
15044000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
46739000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4596000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
42143000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
46739000
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1800000
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1800000
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y7M6D
CY2021Q1 vygr Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
0.080
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43144000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
42143000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
43409000
CY2021Q1 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2020Q4 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4596000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4198000
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4596000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4198000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44410000
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8012000
CY2021Q1 vygr Additions To Contract With Customer Assets
AdditionsToContractWithCustomerAssets
3363000
CY2021Q1 vygr Deductions To Contract With Customer Assets
DeductionsToContractWithCustomerAssets
7122000
CY2021Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
4253000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
43689000
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3632000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
40057000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
261109
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3601000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4040000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3601000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4040000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5485078
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.77
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1031704
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.42
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3811
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.27
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
14.01
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6251862
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8016056
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6989053
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.59
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3165450
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.18
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M

Files In Submission

Name View Source Status
0001558370-21-006582-index-headers.html Edgar Link pending
0001558370-21-006582-index.html Edgar Link pending
0001558370-21-006582.txt Edgar Link pending
0001558370-21-006582-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vygr-20210331.xsd Edgar Link pending
vygr-20210331x10q.htm Edgar Link pending
vygr-20210331x10q006.jpg Edgar Link pending
vygr-20210331x10q_htm.xml Edgar Link completed
vygr-20210331xex31d1.htm Edgar Link pending
vygr-20210331xex31d2.htm Edgar Link pending
vygr-20210331xex32d1.htm Edgar Link pending
vygr-20210331_cal.xml Edgar Link unprocessable
vygr-20210331_def.xml Edgar Link unprocessable
vygr-20210331_lab.xml Edgar Link unprocessable
vygr-20210331_pre.xml Edgar Link unprocessable